Hugel Inc145020
▲ PositiveCapitalrelevance
Record first-half earnings with strong sales and profit growth.
Impact on stocks 1
Health Care
Hugel IncHugel reports record first-half earnings driven by strong botulinum toxin growth
Earnings
Hugel Inc. reported record first-half 2026 earnings, with consolidated net sales jumping 27.2% on-year to KRW254.5 billion, operating profit rising 8.4% to KRW103.7 billion, and net income climbing 23.5% to KRW85.3 billion. The performance was primarily driven by solid demand for botulinum toxin, which saw first-half net sales increase 46.6% on-year to KRW149.4 billion. Global net sales of botulinum toxin and hyaluronic acid dermal fillers and skinboosters reached KRW162.1 billion, accounting for about 64% of total net sales, while the cosmetics and other businesses posted KRW39 billion, up 31.7%. Second-quarter operating profit remained largely unchanged on-year at KRW56 billion, reflecting strategic investments to support long-term growth including the rollout of U.S. direct sales operations. The company saw balanced growth across markets, with first-half net sales in the Americas more than doubling on-year and both Asia-Pacific and Europe & other markets increasing by the mid-to-high 20% range.
Hugel IncRecord first-half earnings with strong sales and profit growth.